Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Halia-BIO

More Like This

PR Newswire associated0

Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

PR Newswire associated0

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

PR Newswire associated0

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

PR Newswire associated0

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

PR Newswire associated0

Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets

PR Newswire associated0

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

Tiziana Life Sciences to Present at the 37th Annual Roth Conference